Dawn Jeannerat, NP
Nurse Practitioner · Clarion, PANPI 1922471556
Payments from drug & device makers
Across 562 payments — averaging $138.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$39K
- Regeneron Healthcare Solutions, Inc.$23K
- Sanofi$3K
- Philips North America LLC$3K
- AstraZeneca$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- plus $6K from 29 others
Across 23 payments — averaging $192.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$3K
- Sanofi US Services Inc.$1K
What the payments were for
- Consulting fees$1,2442%
- Speaking & faculty fees$40,83452%
- Travel & lodging$18,72824%
- Food & beverage$16,49621%
- Education$4841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 164 | $38,940 |
| Regeneron Healthcare Solutions, Inc. | 71 | $23,314 |
| Sanofi | 32 | $3,485 |
| Philips North America LLC | 44 | $2,756 |
| AstraZeneca(2 entities) | 84 | $2,409 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $1,297 |
| Actelion Pharmaceuticals US, Inc. | 27 | $949 |
| Pinnacle Biologics, Inc | 5 | $936 |
| Noah Medical Corporation | 3 | $665 |
| Boehringer Ingelheim | 15 | $663 |
| Amgen | 8 | $420 |
| Mylan Specialty L.p. | 10 | $410 |
| Astrazeneca UK Limited | 1 | $218 |
| Electromed, Inc. | 15 | $209 |
| United Therapeutics Corporation | 16 | $201 |
| Regeneron | 3 | $127 |
| Johnson & Johnson(2 entities) | 3 | $123 |
| Baxter Healthcare | 5 | $112 |
| Pfizer | 6 | $108 |
| Verona Pharma, Inc. | 1 | $93 |
| Sanofi-aventis U.S. LLC | 1 | $89 |
| Merck | 4 | $89 |
| Pulmonx Corporation | 3 | $57 |
| Harmony Biosciences LLC | 2 | $53 |
| Novo Nordisk | 2 | $42 |
| Genentech USA, Inc. | 2 | $40 |
| Ambu Inc. | 1 | $35 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $30 |
| Nabriva Therapeutics, PLC | 2 | $28 |
| Resmed Corp | 1 | $28 |
| Rocket Medical LLC | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $18 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$78,004 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 59 | $256,507 |
| OfevNintedanib Esylate | 19 | $243,796 |
| GlassiaAlpha-1-Proteinase Inhibitor | 15 | $180,738 |
| NucalaMepolizumab | 36 | $170,528 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 11 | $137,638 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 158 | $125,307 |
| Dupixent SyringeDupilumab | 30 | $112,217 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 46 | $22,099 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 29 | $19,485 |
| Spiriva RespimatTiotropium Bromide | 29 | $14,296 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $13,843 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 61 | $11,042 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $4,790 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $3,042 |
| Montelukast Sodium | 178 | $2,622 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Anoro Ellipta, Breo Ellipta | $38,940 | $331,777273 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $663 | $277,57777 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $1,297 | $180,73815 claims |
| AstraZenecaSymbicort | $2,409 | $4,79020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Other nurse practitioner in Clarion
- Patricia ManganPhiladelphia$360K
- Lisa CocoPhiladelphia$230K
- Elisabeth BaidalPhiladelphia$151K
- Suzanne McGettiganPhiladelphia$108K
- Tracey WileyChambersburg$101K
- Pamela LorditchJohnstown$81K
- Nana BernaskoHershey$81K
- Carolyn GrandePhiladelphia$71K
- Nicole WaetzmanStrafford$66K
- Faith MutalePhiladelphia$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.